Cargando…
Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma
BACKGROUND: The treatment of oral squamous cell carcinoma (OSCC) following early detection is associated with good outcomes. Therefore, the survival and prognosis of OSCC patients could be hugely improved by identifying reliable biomarkers for the early diagnosis of the disease. Our previous methyla...
Autores principales: | Lai, Yi-Hui, He, Ru-Yin, Chou, Jian-Liang, Chan, Michael W-Y, Li, Yu-Fen, Tai, Chien-Kuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160550/ https://www.ncbi.nlm.nih.gov/pubmed/25179542 http://dx.doi.org/10.1186/s12967-014-0237-7 |
Ejemplares similares
-
METH-2 silencing and promoter hypermethylation in NSCLC
por: Dunn, J R, et al.
Publicado: (2004) -
Aberrant DNA hypermethylation-silenced SOX21-AS1 gene expression and its clinical importance in oral cancer
por: Yang, Cheng-Mei, et al.
Publicado: (2016) -
Pervasive promoter hypermethylation of silenced TERT alleles in human cancers
por: Esopi, David, et al.
Publicado: (2020) -
DNA Methylation Profiling Revealed Promoter Hypermethylation-induced Silencing of p16, DDAH2 and DUSP1 in Primary Oral Squamous Cell Carcinoma
por: Khor, Goot Heah, et al.
Publicado: (2013) -
BCL7A is silenced by hypermethylation to promote acute myeloid leukemia
por: Patiño-Mercau, Juan Rodrigo, et al.
Publicado: (2023)